Cathie Wood's Latest Contrarian Bets Signal Confidence in Beaten-Down Growth Stocks
Cathie Wood's $ARK Invest made strategic additions to three depressed growth stocks on Monday, doubling down on her conviction that market dislocations have created compelling entry points. The moves—adding to positions in Joby Aviation ($JOBY), GeneDx Holdings ($GNEDX), and DraftKings ($DLTR)—underscore the prominent investor's willingness to accumulate shares when valuations have compressed amid broader market volatility. Each company operates in a distinct high-growth sector but shares a common characteristic: substantial declines from peak valuations that have deterred mainstream investors.
The timing of Ark's purchases carries particular significance given Joby Aviation's recent announcement of a White House partnership that will enable electric vertical takeoff and landing (eVTOL) aircraft services across 10 states later this year. This regulatory validation represents a watershed moment for the nascent urban air mobility sector, transforming what was once speculative technology into an imminent commercial reality with governmental backing.
The Three Stocks Behind Wood's Conviction Play
Joby Aviation, the eVTOL manufacturer, has seen its stock price crater alongside broader weakness in electric vehicle and transportation technology names. The company's path to profitability remains capital-intensive, yet the White House partnership fundamentally de-risks the regulatory and market adoption question that has plagued the sector. This governmental endorsement—enabling operations in 10 states during 2024—transforms Joby from a speculative venture into a company with concrete near-term revenue catalysts.
GeneDx Holdings operates in the genetic testing and diagnostics space, a sector benefiting from secular tailwinds including:
- Declining costs of genetic sequencing
- Growing adoption of precision medicine
- Expanding insurance coverage for genetic diagnostics
- Aging global population seeking advanced healthcare solutions
Despite these favorable fundamentals, the stock has declined substantially from previous peaks, likely due to market rotation away from healthcare technology and heightened scrutiny on diagnostic companies' reimbursement rates.
DraftKings, the sports wagering platform, operates in one of the fastest-growing betting markets globally. The company faces intensifying competition and unit economics pressures from customer acquisition costs, yet maintains leadership in a sector still in early penetration phases across numerous U.S. states and international markets.
Market Context: Why Growth Stocks Are Attractive Again
Ark Invest's accumulation strategy reflects a calculated thesis that technology and innovation stocks have been oversold relative to their long-term growth prospects. The 2023-2024 market environment has been particularly punitive toward unprofitable growth companies, as rising interest rates have compressed valuations across the sector.
The competitive landscape differs markedly across Ark's three new positions:
- eVTOL sector: Limited competition, with Joby positioned alongside Lilium and Archer Aviation in a race for regulatory approval and first-mover advantages
- Genetic testing: Highly fragmented with competitors including Invitae and Myriad Genetics, though GeneDx's focus on rare disease diagnosis provides a defensible niche
- Sports betting: Extremely crowded with incumbents like FanDuel (owned by Flutter Entertainment), BetMGM, and numerous regional operators
The regulatory environment has also shifted favorably for two of these sectors. Joby's White House partnership signals governmental commitment to urban air mobility infrastructure. Meanwhile, sports betting has achieved quasi-mainstream acceptance across most major U.S. states, reducing regulatory uncertainty that previously constrained DraftKings' growth.
Investor Implications: Bargain Hunting in High-Conviction Sectors
For investors evaluating Ark's moves, several implications merit consideration:
Valuation Reset: All three stocks have experienced severe valuation compression, creating asymmetric risk-reward profiles. Wood's accumulation suggests she believes current prices fail to account for long-term value creation potential.
Sector Rotation Indicator: Ark's activity may signal a broader market shift away from mega-cap technology and back toward smaller-cap innovation names that were devastated during 2022-2023's rate-hiking cycle.
De-risking Through Catalysts: The Joby White House partnership exemplifies how regulatory validation and near-term catalysts can revalue previously speculative businesses. Both GeneDx and DraftKings possess multiple potential catalysts—expanded insurance coverage and additional state sports betting legalization, respectively—that could reignite investor interest.
Concentration Risk: Ark's funds maintain concentrated positions in disruptive technology themes. While this creates outsized upside potential, it also compounds downside risk if any thesis deteriorates. Investors considering Ark ETFs should understand their high active management fees and significant sector concentration.
The broader question these purchases raise concerns market efficiency: Has the 2023 rally left truly transformational companies undervalued, or are bearish market participants justified in their skepticism of unprofitable growth? Ark's conviction, backed by substantial capital deployment, suggests the investor believes the former.
Forward-Looking Perspective
Cathie Wood's accumulation of Joby Aviation, GeneDx Holdings, and DraftKings represents a calculated bet that innovation-driven companies have been unfairly punished by macro headwinds. The eVTOL space has achieved governmental legitimacy, genetic testing benefits from secular healthcare trends, and sports betting operates in a de-risked regulatory environment with structural growth drivers.
These moves may prove prescient if innovation leadership eventually regains investor favor, or contrarian if growth sectors face additional headwinds. Either way, Ark's willingness to deploy capital into oversold positions underscores the fundamental tension in modern markets: whether equities trade on earnings power and growth trajectories or continue responding primarily to interest rate expectations and macro sentiment. The performance of these three holdings will provide investors with meaningful data points on that question throughout 2024.